Development of a minimal saponin vaccine adjuvant based on QS-21
Open Access
- 1 June 2014
- journal article
- research article
- Published by Springer Nature in Nature Chemistry
- Vol. 6 (7) , 635-643
Abstract
Adjuvants are materials added to vaccines to enhance the immunological response to an antigen. QS-21 is a natural product adjuvant under investigation in numerous vaccine clinical trials, but its use is constrained by scarcity, toxicity, instability and an enigmatic molecular mechanism of action. Herein we describe the development of a minimal QS-21 analogue that decouples adjuvant activity from toxicity and provides a powerful platform for mechanistic investigations. We found that the entire branched trisaccharide domain of QS-21 is dispensable for adjuvant activity and that the C4-aldehyde substituent, previously proposed to bind covalently to an unknown cellular target, is also not required. Biodistribution studies revealed that active adjuvants were retained preferentially at the injection site and the nearest draining lymph nodes compared with the attenuated variants. Overall, these studies have yielded critical insights into saponin structure–function relationships, provided practical synthetic access to non-toxic adjuvants, and established a platform for detailed mechanistic studies.Keywords
This publication has 35 references indexed in Scilit:
- Modern Subunit Vaccines: Development, Components, and Research OpportunitiesChemMedChem, 2013
- First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African ChildrenNew England Journal of Medicine, 2011
- ISCOMATRIX Adjuvant Combines Immune Activation with Antigen Delivery to Dendritic Cells In Vivo Leading to Effective Cross-Priming of CD8+ T CellsThe Journal of Immunology, 2011
- Natural and synthetic saponin adjuvant QS-21 for vaccines against cancerExpert Review of Vaccines, 2011
- Unmet needs in modern vaccinologyVaccine, 2010
- Design and Synthesis of Potent Quillaja Saponin Vaccine AdjuvantsJournal of the American Chemical Society, 2010
- Synthesis of QS‐21‐Xylose: Establishment of the Immunopotentiating Activity of Synthetic QS‐21 Adjuvant with a Melanoma VaccineAngewandte Chemie International Edition, 2008
- The safety and tolerability of an HIV-1 DNA prime–protein boost vaccine (DP6-001) in healthy adult volunteersVaccine, 2008
- Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant functionVaccine, 1995
- Radioiodination techniques for small organic moleculesChemical Reviews, 1982